Maven Securities’s MaxCyte MXCT Stock Holding History

Maven Securities’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-204,175	Closed	-$637K	–	1122
2023 Q3	$637K	Buy	+204,175	New	+$821K	0.01%	750

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities's MXCT Position: Q4 2023 in Review

Maven Securities sold out of MaxCyte (MXCT) in Q4 2023, closing a stake of 204,175 shares — an estimated $637K sold.

Maven Securities first reported a position in MXCT in Q3 2023 and held it in 1 quarter. The position peaked at $637K in Q3 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q4 2023.

Maven Securities reported no remaining MaxCyte position as of Q4 2023 after selling out during the quarter.
Maven Securities sold 204,175 MaxCyte shares in Q4 2023, an estimated $637K.
Maven Securities first reported a position in MaxCyte in Q3 2023 and held it in 1 quarter.
Maven Securities's MaxCyte position peaked at $637K in Q3 2023.
120 funds tracked by Wall St. Rank held MaxCyte as of Q4 2023.

Based on Maven Securities's 13F filing for Q4 2023, filed 12 Feb 2024.